We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.
Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Genomics Data Analysis System Speeds Drug R&D

By BiotechDaily International staff writers
Posted on 25 Nov 2009
Print article
A new genomics data-analysis system was designed for advancing life science research, discovery, and development.

Tibco Software, Inc. (Palo Alto,CA, USA), together with Integromics (Madrid, MA, USA), a provider of software systems for data management and data analysis in genomics, proteomics, and drug discovery, reported that Integromics Biomarker Discovery 2.0 for Tibco Spotfire is a new solution that sets the standard for advanced methods of data access, normalization, pattern detection, treatment comparison, and functional analysis for scientists analyzing genomic expression data. This powerful platform plays a pivotal role in leveraging the considerable investment in gene expression technologies that the pharmaceutical and biotechnology industries have made in the last 10 years. Gaining new insights into disease biology, mechanism of action and drug safety will be a key differentiator in early drug discovery.

The scientific and workflow knowledge of Integromics--combined with the adaptability and ease of use of the Tibco Spotfire enterprise analytics platform--provides pharmaceutical, biotechnology, and academic research groups a powerful genomic data analysis environment that rapidly finds and categorizes complex patterns. With interactive analysis and high-impact visualization capabilities, Integromics Biomarker Discovery 2.0 for Tibco Spotfire quickly reveals insights and unexpected relationships in genomics data. This allows researchers and scientists to examine the expression and annotation dimensions of their data and perform a variety of numerical analyses--all in one application. Pharmaceutical companies can also use Tibco Spotfire as a flexible analytics platform to combine and analyze new types of data to pursue more quickly hypotheses and research strategies.

"Having developed microarray analytics for over five years and benefited from a successful partnership with Spotfire for several years now, we are confident that this combined solution will provide researchers with a powerful environment to accelerate discovery and provide accurate, up-to-date analytics from a single reliable source,” said Imad Yassin, global commercial director, Integromics. "With this set of tools, life-science researchers can ask and answer new questions and create an advanced problem solving environment.”

"Genomics research typically involves measuring the activity of thousands of genes in many different treatments or conditions, and combining that information with other data to uncover new insight into the biology of disease and treatment,” said Mark Lorion, vice president of marketing, Tibco Spotfire. "This solution helps researchers and scientists address one of the industry's long-standing challenges of creating knowledge from mass data by easily integrating multiple data sources and transforming data into an interactive decision-making asset.”

Integromics develops information technology (IT) solutions for life sciences (genomics and proteomics) in two strategic areas: data management/integration and intelligent data analysis. Over the years, the company has developed a network of collaborations and partnerships with leading industry and academic organizations to provide complete technological solutions that enable scientists to make new discoveries from their research data. Integromics operates globally in Asia Pacific, Europe, and the United States.

Tibco Software is a leading provider of enterprise analytics software for next generation business intelligence. Distinguished by its speed to insight and adaptability to specific business challenges, Spotfire rapidly reveals unseen threats and new opportunities, creating significant economic value.

Related Links:

Tibco Software

Print article



view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2019 Globetech Media. All rights reserved.